What impact does age have on the effectiveness of multiple sclerosis (MS) therapy in real-world clinical practice? How do the outcomes differ for patients treated with teriflunomide considering their age and previous therapy? The authors of a study published this year in the journal Therapeutic Advances in Neurological Disorders focused on the efficacy and safety of teriflunomide in real-world clinical practice with regard to age and prior treatment.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
